School of Pharmacy, The University of Queensland, St Lucia, Campus, Brisbane, Queensland, Australia.
Pain Med. 2010 Apr;11(4):550-61. doi: 10.1111/j.1526-4637.2010.00821.x. Epub 2010 Mar 1.
This preliminary study assessed possible relationships between plasma and/or cerebrospinal fluid (CSF) concentrations of the pleiotropic cytokine, interleukin (IL)-6, the anti-inflammatory cytokine, IL-10, and levels of pain reported by patients receiving intrathecal (i.t.) opioids.
A prospective study quantifying IL-6 and IL-10 concentrations using enzyme-linked immunoassays in samples of plasma and CSF as well as assessment of pain scores in patients receiving intrathecal opioids for management of chronic noncancer pain.
Outpatient pain clinics.
Patients with chronic pain receiving intrathecal morphine or hydromorphone alone or in combination with local anesthetics.
Two groups of patients were studied. The first group (n = 50) had been receiving long-term i.t. opioids by chronically implanted pump for approximately 5 years; paired samples of plasma and CSF were collected at the time of i.t. pump refill. For the second patient group (n = 10), possible temporal changes in the plasma and/or CSF concentrations of IL-6 and IL-10 were investigated for 3 months after initiation of i.t. opioid infusions.
For patients receiving long-term i.t. opioid infusions, there were significant inverse correlations (P < or = 0.05) between pain intensity and the plasma (but not CSF) IL-10 and IL-6 concentrations. Despite the considerable inter-patient variability in the CSF concentrations of IL-6 in the long-term cohort, the mean CSF IL-6 concentration was approximately fivefold higher in patients receiving long-term i.t. opioids relative to those receiving i.t. opioids for only 3 months.
The significant inverse correlations observed between pain intensity and the plasma IL-6 and IL-10 concentrations in patients receiving longterm i.t. opioids for chronic pain management, suggests that these cytokines are worthy of further investigation as possible biomarkers of persistent pain.
本初步研究评估了多效细胞因子白细胞介素（IL）-6 和抗炎细胞因子 IL-10 的血浆和/或脑脊液（CSF）浓度与接受鞘内（i.t.）阿片类药物治疗的患者报告的疼痛之间可能存在的关系。
使用酶联免疫吸附试验（ELISA）定量测定接受鞘内阿片类药物治疗慢性非癌性疼痛的患者的血浆和 CSF 样本中的 IL-6 和 IL-10 浓度，并评估疼痛评分的前瞻性研究。
门诊疼痛诊所。
接受鞘内吗啡或氢吗啡酮单独或与局部麻醉剂联合治疗的慢性疼痛患者。
研究了两组患者。第一组（n=50）长期通过慢性植入泵接受 i.t. 阿片类药物治疗，大约 5 年；在 i.t. 泵补液时收集血浆和 CSF 的配对样本。对于第二组患者（n=10），在开始 i.t. 阿片类药物输注后的 3 个月内，研究了血浆和/或 CSF 中 IL-6 和 IL-10 浓度的可能时间变化。
对于接受长期 i.t. 阿片类药物输注的患者，疼痛强度与血浆（但不是 CSF）IL-10 和 IL-6 浓度之间存在显著的负相关（P≤0.05）。尽管长期队列中 CSF 中 IL-6 的患者间变异性很大，但接受长期 i.t. 阿片类药物治疗的患者的 CSF IL-6 浓度平均约为接受 i.t. 阿片类药物治疗仅 3 个月的患者的五倍。
在接受长期 i.t. 阿片类药物治疗慢性疼痛管理的患者中，观察到疼痛强度与血浆 IL-6 和 IL-10 浓度之间的显著负相关，表明这些细胞因子值得进一步研究，作为持续性疼痛的潜在生物标志物。
